Artículo
Emerging pharmacological treatment options for MAFLD
Autor/es | Rojas, Ángela
Lara-Romero, Carmen Muñoz Hernández, Rocío Gato, Sheila Ampuero Herrojo, Javier Romero Gómez, Manuel |
Departamento | Universidad de Sevilla. Departamento de Fisiología Universidad de Sevilla. Departamento de Medicina Universidad de Sevilla. Instituto de Biomedicina de Sevilla (IBIS) |
Fecha de publicación | 2022 |
Fecha de depósito | 2023-10-26 |
Publicado en |
|
Resumen | Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and
incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight,
type 2 diabetes mellitus, and at least two ... Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk, increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis, necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and liver decompensations including hepatocellular carcinoma development. The limitation of approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent pathways and targets with evidence results in phase II/III iclinical trials. |
Cita | Rojas, Á., Lara-Romero, C., Muñoz Hernández, R., Gato, S., Ampuero Herrojo, J. y Romero Gómez, M. (2022). Emerging pharmacological treatment options for MAFLD. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/20420188221142452. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Emerging....pdf | 158.2Kb | [PDF] | Ver/ | |